EUVIMEDEUVIMED entdecken
Open Access

Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates

Uttam Satyal iD, Henkel Valentine iD, David Liu iD, Michael Slifker iD, Costas D Lallas, Edouard J Trabulsi iD, Laura Bukavina iD, Lauren Szeto, Jean H Hoffman-Censits iD, Kent W Mouw iD, Bishoy M Faltas iD, Petros Grivas iD und 17 weitere

JCO Precision Oncology · 2024

DOI: 10.1200/po.23.00362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Uttam Satyal und 28 weiteren Autor:innen. Beteiligte Einrichtung: Fox Chase Cancer Center, Philadelphia, PA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cystectomy, Neoplasm Staging, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE There is significant interest in identifying complete responders to neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) to potentially avoid removal of a pathologically benign bladder. However, clinical restaging after NAC is highly inaccurate. The objective of this study was to develop a next-generation sequencing–based molecular assay using urine to enhance clinical staging of patients with bladder cancer. METHODS Urine samples from 20 and 44 patients with bladder cancer undergoing RC were prospectively collected for retrospective analysis for molecular correlate analysis from two clinical trials, respectively. The first cohort was used to benchmark the assay, and the second was used to determine the performance characteristics of the test as it correlates to responder status as measured by pathologic examination. RESULTS First, to benchmark the assay, known mutations identified in the tissue (M T ) of patients from the Accelerated Methotrexate, Vinblastine, Doxorubicin, Cisplatin trial (ClinicalTrials.gov identifier: NCT01611662 , n = 16) and a cohort from University of California-San Francisco (n = 4) were cross referenced against mutation profiles from urine (M U ). We then determined the correlation between M U persistence and residual disease in pre-RC urine samples from a second prospective clinical trial (The pT0 trial; ClinicalTrials.gov identifier: NCT02968732 ). Residual M U status correlated strongly with residual disease status (pT0 trial; n = 44; P = .0092) when M U from urine supernatant and urine pellet were assessed separately and analyzed in tandem. The sensitivity, specificity, PPV, and NPV were 91%, 50%, 86%, and 63% respectively, with an overall accuracy of 82% for this second cohort. CONCLUSION M U are representative of M T and thus can be used to enhance clinical staging of urothelial carcinoma. Urine biopsy may be used as a reliable tool that can be further developed to identify complete response to NAC in anticipation of safe RC avoidance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCystectomyNeoplasm StagingBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedBiopsyRetrospective StudiesNeoadjuvant Therapy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Fox Chase Cancer Center, Philadelphia, PA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Broad Institute of Harvard and MIT, Cambridge, MA.
  • Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
  • Department of Urology, Albert Einstein Medical Center, Philadelphia, PA.
  • Department of Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD.

ORCID-Profile: Uttam Satyal, Henkel Valentine, David Liu, Michael Slifker, Edouard J Trabulsi, Laura Bukavina, Jean H Hoffman-Censits, Kent W Mouw, Bishoy M Faltas, Petros Grivas, Eliezer M Van Allen, Daniel M Geynisman, John P O'Neill, Johnathan Drevik, Sarah S Christianson, Andres F Correa, Eric A Ross, Matthew R Zibelman, Elizabeth R Plimack, Philip H Abbosh

Förderung

  • NCI NIH HHS
  • NIH HHS

Zitieren

APA

Satyal, U., Valentine, H., Liu, D., Slifker, M., Lallas, C. D., Trabulsi, E. J., Bukavina, L., Szeto, L., Hoffman-Censits, J. H., Mouw, K. W., Faltas, B. M., Grivas, P., Ibragimova, I., Porten, S. P., Van Allen, E. M., Geynisman, D. M., Parker, D. C., O'Neill, J. P., Drevik, J., …, & Abbosh, P. H. (2024). Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates. JCO Precision Oncology. https://doi.org/10.1200/po.23.00362

Vancouver

Satyal U, Valentine H, Liu D, Slifker M, Lallas CD, Trabulsi EJ, et al. Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates. JCO Precision Oncology. 2024. doi:10.1200/po.23.00362

BibTeX
@article{Satyal2024,
  author = {Satyal, Uttam and Valentine, Henkel and Liu, David and Slifker, Michael and Lallas, Costas D and Trabulsi, Edouard J and Bukavina, Laura and Szeto, Lauren and Hoffman-Censits, Jean H and Mouw, Kent W and Faltas, Bishoy M and Grivas, Petros and Ibragimova, Ilsiya and Porten, Sima P and Van Allen, Eliezer M and Geynisman, Daniel M and Parker, Daniel C and O'Neill, John P and Drevik, Johnathan and Christianson, Sarah S and Ginzburg, Serge and Correa, Andres F and Uzzo, Robert G and Ross, Eric A and Zibelman, Matthew R and Ghatalia, Pooja and Plimack, Elizabeth R and Kutikov, Alexander and Abbosh, Philip H},
  title = {Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.23.00362}
}
Kostenlos starten →